FluoGuide announces regulatory approval from Danish Medicines Agency to commence Phase I/II clinical trial with FG001 in guiding surgery of high grade glioma including glioblastoma

Copenhagen, Denmark, 3 September 2020 – FluoGuide A/S (“FluoGuide” or “the Company”) is pleased to announce that the company has received regulatory approval for the first clinical phase I/II trial. It is the first time that our lead uPAR targeting product – FG001 – will be used to guide oncology surgery.

The release as fetched from its publisher. fluoguide.com ↗